Details of the Drug Formulations

General Information of Drug (ID: DMN4CV5)

• Drug Name: Calcidiol Drug Info
• Synonyms: Calcifediolum; Calcifidiol; Delakmin; VDY; Calcifediol anhydrous; BML2-E02; Calcifediolum [INN-Latin]; Ro 8-8892; U-32070E; (1R,3Z)-3-[(2E)-2-[(1R,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol; (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol; (3S,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol; (3S,5Z,7E)-9,10-secocholesta-5,7,10-triene-3,25-diol; (3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol; (5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol; (5Z,7E)-9,10-Seco-5,7,10(19)-cholestatrien-3beta,25-diol; 25(OH)D3; 25-(OH)Vitamin D3; 25-Hydroxycholecalciferol; 25-Hydroxycholecalciferol (Calcifediol); 25-Hydroxycholescalciferol; 25-Hydroxyvitamin D; 25-Hydroxyvitamin D3 monohydrate; 25-hydroxyvitamin D3; 3-{2-[1-(5-HYDROXY-1,5-DIMETHYL-HEXYL)-7A-METHYL-OCTAHYDRO-INDEN-4-YLIDENE]-ETHYLIDENE}-4-METHYLENE-CYCLOHEXANOL; 5,6-cis-25-Hydroxyvitamin D3; 5,6-trans-25-Hydroxycholescalciferol; 5,6-trans-9,10-Seco-5,7,10(19)-cholestatrien-3beta,25-diol; 9,10-Secocholesta-5,7,10(19)-triene-3beta,25-diol

Indication

Disease Entry	ICD 11	Status	REF
Hypophosphatemia		Approved	[1]
Renal osteodystrophy		Approved	[2]
Rickets	5B57	Approved	[3]
Vitamin D deficiency	5B57	Approved	[4]
Autosomal dominant hypocalcemia	5A50.0Y	Investigative	[5]

• Therapeutic Class: Vitamins
• Cross-matching ID:
  PubChem CID: 5283731
  ChEBI ID: CHEBI:17933
  CAS Number: 19356-17-3
  TTD ID: D02VPX
  INTEDE ID: DR0259
  ACDINA ID: D00089

Full List of Drug Formulations Containing This Drug

Calcifediol 0.03 mg capsule

Company	Formulation ID	FDA Description
OPKO Pharmaceuticals	F03145	Butylated hydroxytoluene; Fd&c blue no. 1; Isopropyl alcohol; Sorbitol; Propylene glycol; Titanium dioxide; Water; Medium-chain triglycerides; Alcohol; Carrageenan; Diacetyltartaric and fatty acid esters of glycerol; Hydroxypropyl corn starch (5% substitution by weight); Hypromelloses; Lauroyl peg-32 glycerides; Mineral oil; Paraffin; Sodium phosphate, dibasic; Sorbitan

References

• [1] Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant. 2007 May;7(5):1193-200.
• [2] Patterns of renal osteodystrophy 1?year after kidney transplantation. Nephrol Dial Transplant. 2021 Nov 9;36(11):2130-2139.
• [3] Correction of vitamin D status by calcidiol: pharmacokinetic profile, safety, and biochemical effects on bone and mineral metabolism of daily and weekly dosage regimens. Osteoporos Int. 2017 Nov;28(11):3239-3249.
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6921).
• [5] A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.